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CASE REPORT
The therapeutic response in Gorham’s 
syndrome to the beta-blocking agent 
propranolol is correlated to VEGF-A, but not 
to VEGF-C or FLT1 expression
Jessica Baud1,2†, Abderrahim Lomri1,2†, Denis Graber3 and Andreas Bikfalvi1,2*
Abstract 
Background: Gorham’s syndrome is a rare illness of unknown etiology. It is characterized by a local proliferation of 
blood or lymphatic vessels that in bones leads to progressive resorption and destruction. The cause of the disease is 
not elucidated, and therapeutic options remain limited.
Case presentation: We report herein the case of a young female Caucasian patient aged 18 years with diffuse 
Gorham syndrome. In tissue specimens angiogenesis and massive lymphangiogenesis as well as the expression of 
vascular endothelial growth factor-A (VEGF-A) and neuropilins was observed. Lymphangiogenesis is a prominent 
feature of the disease and a number of lymphatic markers were found to be expressed, however only VEGF-A, but not 
vascular endothelial growth factor-C (VEGF-C) was found to be elevated in the circulation. Circulating levels of soluble 
VEGF receptor-1 were also not elevated. Furthermore, the patient responded favorably and the disease was stabilized 
following treatment with the beta-blocking agent Propranolol alone which acts on VEGF-A alone, but not on soluble 
VEGF receptor-1 levels.
Conclusion: This suggests that the disease is dependent on VEGF-A, but on neither VEGF-C, the major driver of lym-
phangiogenesis, nor FLT1. Furthermore, Propranolol acts on VEGF-A but not FLT1 expression.
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Background
Gorham’s syndrome is a rare illness of unknown etiology. It 
is characterized by a local proliferation of blood or lymphatic 
vessels that leads to progressive resorption and destruction 
in bones [1]. The lesions consist of numerous thin walled 
vascular or lymphatic channels in association with massive 
osteolysis. The lesions may extend into adjacent bones, vis-
cera or soft tissue, and may be accompanied by local fibrosis. 
The cause of the disease is not elucidated. The therapeutic 
options to treat this condition are still limited.
The use of Propranolol has been reported previ-
ously in infantile hemangioma [2], pediatric lymphatic 
malformation [3] and in Gorham’s syndrome [4, 5]. Vas-
cular endothelial growth factor-A (VEGF-A) was previ-
ously shown to be increased in Gorham’s syndrome, and 
Propranolol to be able to decrease VEGF-A levels [5, 6]. 
However, the full spectrum of VEGF family members 
and, in particular, vascular endothelial growth factor-C 
(VEGF-C) and vascular endothelial growth factor recep-
tor-1/fms-like tyrosine kinase-1 (VEGFR1 or FLT-1) has 
not been investigated and no definite explanation for the 
therapeutic effect was given.
Case presentation
We report herein the case of young Caucasian female 
patient of 18 years of age with diffuse Gorham’s syndrome. 
Surprisingly, since lymphangiogenesis is a prominent fea-
ture in the disease, VEGF-A but not VEGF-C was found 
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to be elevated in the patient’s circulation. Circulating levels 
of soluble FLT-1 were also not elevated. Furthermore, the 
patient responded favorably to the β-blocking agent Pro-
pranolol which acts on VEGF-A, but not on FLT-1 levels.
Clinical symptoms were already present at the age of 9. At 
diagnosis at the age of 15, the patient exhibited pronounced 
diffuse lesions in bone and soft tissue (Figure  1a). Fur-
thermore, this was accompanied by severe gynecological 
symptoms with loss of chylous/lymphatic liquid. Biop-
sies of cervical lesions revealed pronounced angiogenesis 
and lymphangiogenesis (Figure 1b). VEGF-A was strongly 
expressed at the site of the lesion along with neuropilin 1 
a








Figure 1 a Radiological images of spleen (upper image) and pelvic region (lower image) at diagnosis. Multiple hypodense nodules are present in 
the spleen and fluid accumulation in the pelvic region is seen. b Immunohistochemistry of cervix tissue for blood and lymphatic vessel markers. 
Blood vessels were revealed by cluster of differentiation 31 and 34 (CD31, CD34), neuropilin-1 (NRP1, arterial marker), neuropilin-2 (NRP2, venous 
marker) immunostaining. Lymphatics were detected by Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) and Podoplanin immunostain-
ing. Blood and lymphatic vessels are detected both by CD31 and NRP2 immunostaining. Furthermore, VEGF-A was significantly expressed in the 
tissue. Areas in the dotted squares are shown at higher magnification in the right hand images for each marker. Scale bars: Left panels 50 µm, right 
panels 20 µm). c Detection of vascular endothelial growth factor-A (VEGF-A) and soluble fms-like tyrosine kinase (FLT-1) in plasma samples by ELISA. 
VEGF-A (black dots) and FLT-1 (blue triangle). We noticed a decrease in VEGF-A levels between July 2013 and May 2014 (after Propranolol treatment) 
compared to April 2013 (before treatment). No significant change was observed for FLT-1. Vascular endothelial growth factor-C (VEGF-C) was below 
detection limit in all samples. Control levels of healthy donors were 75.78 pg/ml and 20.58 ng/ml for VEGF-A and FLT-1 respectively (pooled sample, 
n = 6).
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(NRP1) and 2 (NRP2) (Figure 1b). Plasma VEGF-A levels 
were found to be increased by threefold in comparison to a 
pool (n = 6) of young healthy female donors (control 75.13, 
versus 233.42 pg/ml for the patient). VEGF-A levels before 
treatment were higher than those reported in breast can-
cer patients (136.22 ± 9.95 pg/ml) [7]. The CARE Checklist 
(2013) of information is included in Additional file 1. 
Because of the strong lymphangiogenic component 
found in the biopsy specimen, we hypothesised that 
VEGF-C levels would be highly up-regulated. However, 
in contrast to VEGF-A, we found that circulating VEGF-
C levels were not increased, and were below the limit of. 
Furthermore, circulating FLT-1 (average: 20.58  ng/ml) 
was not increased (Figure 1c).
The fact that pronounced lymphangiogenesis is asso-
ciated with elevated VEGF-A levels is in agreement 
with the observations of Halin et  al. [8]. They have 
shown that inflammation-induced lymphangiogenesis is 
potently blocked by systemic administration of a vascular 
endothelial growth factor (VEGF)-A neutralizing anti-
body and is, thus, dependent on VEGF-A.
In contrast to our results, Ozeki et al. [3] have reported 
that Plasma VEGF-A, C, and D levels are significantly 
higher in patients with lymphatic malformation in com-
parison to control samples. Lymphatic malformation and 
Gorham’s syndrome are not the same clinical entities 
which may explain the differences observed.
Treatment with Propranolol LP (2  mg/kg/day) was 
initiated. The patient responded well to this treatment 
with a disappearance of gynecological symptoms and 
stabilization of bone lesions. VEGF-A levels dropped 
after 3  months of treatment to nearly control levels. At 
7 months of treatment, some increase in VEGF-A levels 
was observed which subsequently decreased again after 
12 months of treatment. The rebound effect at 7 months 
may be due to transient treatment interruption by the 
patient since the heart rate increased during that period.
Morimoto et  al. [5] have demonstrated that a combina-
tion treatment including surgery, interferon and Proprano-
lol is able to improve the clinical evolution of Gorham’s 
syndrome. Furthermore, they showed  with a single meas-
urement (time point) that the combination of surgery, inter-
feron and Propranolol™ is able to decrease VEGF-A levels. 
In opposition to these results, we demonstrate that Propran-
olol alone is able to improve clinical outcome and decreases 
VEGF-A levels measured at several time points. Soluble 
FLT1 could also explain the therapeutic effect because solu-
ble FLT1 is an endogenous inhibitor of VEGF-A. However, 
soluble FLT1 is not up-regulated after Propranolol treat-
ment. Nir et  al. [4] described an effect of Propranolol on 
clinical outcome, but the study did not include measure-
ment of VEGF family members or other angiogenic factors.
Conclusions
Our results suggest that, despite pronounced lymphang-
iogenesis, Gorham’s syndrome seems to be dependent 
on VEGF-A and not on VEGF-C or FLT-1. Furthermore, 
this case demonstrates that Propranolol can be safely 
administered and has striking therapeutic efficacy as a 
single agent in Gorham’s syndrome by decreasing circu-
lating VEGF-A but not by modifying VEGF-C or FLT-1 
levels.
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